PHAXIAM Therapeutics SA

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

Lyon (France), November 13, 2024, at 5:45 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today reports its financial results for the third quarter of 2024.

PHAXIAM Reports Third-Quarter 2024 Financial Information

Lyon (France), November 04, 2024 – 6:00 pm CET - PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announces that it has received Investigational New Drug approval (IND) for its Phase II study, GLORIA, in Prosthetic Joint Infections (PJI) caused by Staphylococcus aureus (S. aureus).

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.

Lyon (France), September 25, 2024 at 5:45 pm CEST – PHAXIAM Therapeutics (Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today provides a business and financial update for the first half of 2024.

PHAXIAM Provides Business and Financial Update For the First Half of 2024

Lyon (France) and Cambridge (MA, US), 28 June 2024 - 5.45 pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announces the results of the shareholder vote following the Combined General Meeting held today, 28 June 2024, at the head office, located 60 avenue Rockefeller, 69008, Lyon.

Results of the Combined General Meeting of 28 June 2024

Lyon (France) and Cambridge (MA, US), 7 June 2024 - 5.45pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announced the availability of preparatory documents for the Combined General Meeting of 28 June 2024.

PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024

PHAXIAM provides Business and Financial Update for the First Quarter of 2024 Webinar (in French) today, May 15, 2024, at 6.00 pm CEST Accelerated clinical efforts to roll-out PHAXIAM's strategy in order to create a global phage-therapy leader in high-value indications Cash and cash equivalents of €5.8 million, as of March 31, 2024 Lyon (France) and Cambridge (MA, US), May 15, 2024, at 5.45 pm CEST – PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today provides a business and financial update for the first quarter of 2024. Thibaut du Fayet, Chief Executive Officer of PHAXIAM Therapeutics, stated: “Almost a year after the creation of PHAXIAM, the company is well on track to become a leading player in phage therapies targeting the most severe bacterial infections.

PHAXIAM provides Business and Financial Update for the First Quarter of 2024

Lyon (France) and Cambridge (MA, US), April 15, 2024 – 7:30am CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the enrolment of the 1st patient in the phase 1 clinical study in endocarditis infection caused by Staphylococcus aureus (S. aureus).

PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus

Lyon (France) and Cambridge (MA, US), 5 April 2024 – 6:00pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announced that it has filed its Universal Registration Document with the Autorité des Marchés Financiers (AMF) in France for the financial year ending 31 December 2023.This document, including the annual financial report and the Board of Directors' report on corporate governance, is available in the "Investors" section of the Company's website (www.phaxiam.com) and on the AMF website (www.amf-france.org). It is also available at the Company's head office (60 avenue Rockefeller, 69008 Lyon).

PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)

PHAXIAM Therapeutics S.A. (ERYFF) Q4 2023 Earnings Call Transcript

Conference call and webcast (English) on Thursday, March 21, 2024

PHAXIAM Announces 2023 Full-Year Results and Provides Business Update

Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces that the Company's voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective. Each ADS represents one ordinary share of the Company. The Company will file a Form 15 with the Securities and Exchange Commission (“SEC”) to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in respect of the ADSs and the ordinary shares. The Company expects that the deregistration of the ADSs under the Exchange Act will become effective 90 days after the filing of the Form 15.

PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market

Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its cash position as of December 31, 2023, and its financial calendar for 2024.

PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

PHAXIAM Therapeutics S.A. (NASDAQ:PHXM ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Thibaut Fayet - CEO Pascal Birman - CMO Eric Soyer - CFO Conference Call Participants Operator Good day, and welcome to the PHAXIAM Therapeutics Business Update and Financial Highlights of Q3 2023.

PHAXIAM Therapeutics S.A. (PHXM) Q3 2023 Earnings Call Transcript

Conference call and webcast (English) on Wednesday, November 15, 2023 at 8:30am ET / 2:30pm CET Ambitious clinical development strategy progressing to create a global phage therapy leader in high-value indications Early access program continues to gain momentum with the treatment of more than 90 patients suffering from severe and resistant infection prosthetic joint infections of the hip or knee (PJI) Cash and cash equivalents of €15.6 million ($16.5 million) as of September 30, 2023 Lyon (France) et Cambridge (MA, US), November 14, 2023, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today provides a business and financial update for the third quarter of 2023. “The third quarter of 2023 was a prolific period during which we managed to move forward with our development programs and benefited from the complementarities of our teams in the context of the merger completion” stated Thibaut du Fayet, Chief Executive Officer of PHAXIAM Therapeutics.

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

Lyon (France) et Cambridge (MA, US), October 24, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bacterial infections, announces the approval of its phase 1 study clinical design in endocarditis infections caused by Staphylococcus aureus (S. aureus) by the French National Agency for the Safety of Medicines and Health Products (ANSM) and the South-East II-Lyon Ethics Committee (Comité de Protection des Personnes - CPP).

PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus

Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bacterial infections, today announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps, has initiated coverage of its shares.

TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendation

PHAXIAM Therapeutics announces high coverage performance of its two anti- Staphylococcus aureus phages over clinical strains.

PHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strains

PHAXIAM Receives Compliance Notice from Nasdaq Lyon (France) et Cambridge (MA, US), October 4, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), today announced that it has received confirmation from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2). With closing bid price of PHAXIAM's American Depositary Shares (“ADSs”) above $1.00 per ADS for the 10 consecutive business days from September 18 through September 29, 2023, PHAXIAM has regained compliance with Listing Rule 5550(a)(2).

PHAXIAM Receives Compliance Notice from Nasdaq

Strategic research partnership between PHAXIAM Therapeutics and Vetophage, a biotechnology company specialized in veterinary phage therapy. Combining expertise in the research of new phages and phage endolysins that could be applied to human health.

PHAXIAM Therapeutics and Vetophage Announce Strategic Research Collaboration

Rapport Financier Semestriel 30 Juin 2023 PHAXIAM.

Rapport Financier Semestriel 30 Juin 2023 PHAXIAM

Formation of PHAXIAM Therapeutics effective as of June 23, 2023, to create a global leader in phage therapies for high-value indications. Ambitious strategy to develop value-creating clinical and regulatory plan in severe and resistant bacterial infections.

PHAXIAM Provides Business and Financial Update For the First Half of 2023

PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae , a new resistant and aggressive bacterial target

PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target

PRESS RELEASE PHAXIAM Therapeutics announces the completion of its reverse share split Lyon (France) and Cambridge (MA, US) , September 18 th , 2023 - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM ) ( the " Company") , announces the completion today of the reverse share split of the shares composing the Company's share capital, as decided by the Executive Director on July 27 th , 2023 , following sub-delegation granted by the Board of Directors on June  23 rd , 2023, made in accordance with the twenty-third extraordinary resolution of the General Shareholders ' Meeting of June 23 rd , 2023 . The reverse share split involved the exchange of ten (10) existing shares with a par value of ten euro cents (€0.10) (the "Existing Shares") for one (1) new share with a par value of one euro (€1) (a "New Share").

News for PHAXIAM Therapeutics SA Stock (PHXM)